Skip to content
OpenCapital
Get started

Mannkind MNKD Convertible Debt (Non-Current)

Convertible Debt (Non-Current) at other companies

Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
$601.77M+94.9%

Other financials

Income statement

See full
Revenue$90.2M+15.1%
Gross profit$82.7M+10.8%
Operating income-$1.7M-107%
Net income-$16.6M-226%
EPS (diluted)-$0.05-225%

Balance sheet

See full
Cash & equivalents$52.8M+11.7%
Total debt$12.2M-9.4%
Total equity-$59.2M-1.0%
Total assets$744.4M+81.5%

Cash flow

See full
Operating cash flow-$5.4M+15.9%
CapEx$1.9M+470%
Free cash flow-$7.2M-8.0%

Valuation

See full
Market cap$1.19B+3.5%
Enterprise value$1.15B+3.0%
P/E228.5×—
P/S3.3×-0.6×

Profitability

See full
Gross margin91.5%-2.6pp
Operating margin23.3%+3.1pp
Net margin9.3%—
FCF margin13.8%—

Returns & leverage

See full
Return on equity-8.8%—
Debt / equity-0.2×—
Current ratio1.9×-0.5×

Where this comes from

Reported directly by Mannkind in its filing.

Tagged under the XBRL concept us-gaap:ConvertibleLongTermNotesPayable.

The official record: Mannkind’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mannkind's convertible debt (non-current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mannkind's convertible debt (non-current)?
Mannkind (MNKD) reported convertible debt (non-current) of $36.05M in Q4 2024.
How has Mannkind's convertible debt (non-current) changed year-over-year?
Mannkind's convertible debt (non-current) decreased by 84.1% year-over-year, from $226.85M to $36.05M.
What is the long-term trend for Mannkind's convertible debt (non-current)?
Over 4 years (2020 to 2024), Mannkind's convertible debt (non-current) has grown at a 63.9% compound annual growth rate (CAGR), from $5M to $36.05M.
What does convertible debt (non-current) mean?
This metric captures the principal amount of debt obligations that can be converted into equity shares, with maturity dates extending beyond one year. It serves as a hybrid financing instrument that provides capital while potentially diluting existing shareholders upon conversion. Analyzing this balance is essential for understanding the company's long-term capital structure, potential future equity dilution, and the impact of financing terms on long-term solvency.